Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors - Related Studies

Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors

This study is ongoing, but not recruiting participants.

Study NCT00003462. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Metastatic Cancer

2	Additional conditions recognized in this trial
		Neoplasm Metastasis

3	More general conditions related to this trial
		Neoplasms
		Neoplastic Processes
		Pathologic Processes

4	Interventions listed in this trial
		busulfan

5	More general drug interventions related to this trial
		Alkylating Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Duke University
		National Cancer Institute (NCI)